Outcomes associated with pharmacotherapy in overactive bladder

References

• Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Am. J. Obstet. Gynecol. 187(1), 116–126 (2002).
   PubMed Web of Science ®Google Scholar
• Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 63(3), 461–465 (2004).
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br. J. Urol. Int. 87(9), 760 (2001).
   Google Scholar
• Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. Int. J. Fertil. Womens Med. 44(2), 56–66 (1999).
   PubMed Web of Science ®Google Scholar
• Yoshida M, Miyamae K, Iwashita H, Otani M, Inadome A. Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology 63 (3 Suppl. 1), 17–23 (2004).
   PubMed Web of Science ®Google Scholar
• US Census Bureau, Projections of the Total Resident Population by 5-year Age Groups, and Sex with Special Age Categories. Population Projections Program, Population Division, US Census Bureau (2000).
   Google Scholar
• Kobelt G, Kirchberger I, Malone-Lee J. Quality-of life aspects of the overactive bladder and the effect of treatment with tolterodine. Br. J. Urol. Int.83,583–590 (1999)
   Google Scholar
• O’Conor R, Johannesson M, Hass S, Kobelt-Nguyen G. Urge incontinence: quality of life and patients’ valuation of symptom reduction. Pharmacoeconomics 14,531–539 (1998).
   PubMed Web of Science ®Google Scholar
• Liberman JN, Hunt TL, Stewart WF et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a US community-based survey. Urology57(6), 1044–1050 (2001).
   PubMed Web of Science ®Google Scholar
• Coyne KS, Payne C, Bhattacharyya SK et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health7(4), 455–463 (2004).
   PubMed Web of Science ®Google Scholar
• Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J. Am. Geriatr. Soc.48,370–374 (2000).
   PubMed Web of Science ®Google Scholar
• Kumar V, Templeman L, Chapple CR et al. Recent developments in the management of detrusor overactivity. Curr. Opin. Urol. 13,285–291 (2003).
   PubMed Web of Science ®Google Scholar
• Nilvebrant L. The mechanism of action of tolterodine. Rev. Contemp. Pharmacother.11,13–27 (2000).
   Web of Science ®Google Scholar
• Chapple CR, Arano P, Bosch JHR et al. YM905 appears effective and well-tolerated in patients with symptomatic idiopathic detrusor overactivity in a european placebo-and tolterodine-controlled Phase 2-dose finding study. Neurourol. Urodyn.21,381 (2002).
   Google Scholar
• Haab F, Stewart L, Dwyer P. Daritenacin, an M3 selective receptor antagonist, is an effective and well-tolerated office-daily treatment for overactive bladder. Eur. Urol. 45, 420–429 (2004).
   PubMed Web of Science ®Google Scholar
• Hunsballe JM, Djurhuus JC. Clinical options for imipramine in the management of urinary incontinence. Urol. Res. 29(2), 118–125 (2001).
   PubMed Web of Science ®Google Scholar
• Millard R, Tuttle J, Moore K et al. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J. Urol.161,1551–1555 (1999).
   PubMed Web of Science ®Google Scholar
• Malone-Lee JG, Eriksson M, Olofsson S et al. Tolterodine versus Oxybutynin Study Group. The comparative tolerability and efficacy of tolterodine 2 mg b.i.d. verus oxybutynin 2.5/5 mg b.i.d. in the treatment of overactive bladder. Proc. ICS 163–164 (1998).
   Google Scholar
• Van Kerrebroek P, Kreder KJ, Jonas U et al. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 57, 414–421 (2001).
   PubMedGoogle Scholar
• Siami P, Seidman LS, Lama D. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT). Clin. Ther. 24, 616–628 (2002).
   PubMed Web of Science ®Google Scholar
• Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur. Urol. 41, 588–595 (2002).
   PubMed Web of Science ®Google Scholar
• Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J. Am. Geriatr. Soc. 50, 799–807 (2002).
   PubMed Web of Science ®Google Scholar
• Appell RA, Sand P, Dmochowski R et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin. Proc. 76, 358–363 (2001).
   PubMed Web of Science ®Google Scholar
• Diokno AC, Appell RA, Sand PK et al., for the OPERA Study Group. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin. Proc. 78(6), 687–695 (2003).
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR et al., for the Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62(2), 237–242 (2003).
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lisec M, Millard R et al. Randomized, double-blind placebo-controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. Urology 172, 1919–1924 (2004).
   Google Scholar
• Chapple CR, Rechberger T, Al-Shukri S et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Br. J. Urol. Int. 93(3), 303–310 (2004).
   Google Scholar
• Rovner ES. Trospium chloride in the management of overactive bladder. Drugs 64(21), 2433–2446 (2004).
   PubMed Web of Science ®Google Scholar
• Zhou Z, Jensen GA. Insurance claims costs for overactive bladder in adults. Value in Health 3(2), 1 (2000).
   Google Scholar
• Hughes DA, Dubois D. Cost–effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics 22(16), 1047–1059 (2004).
   PubMed Web of Science ®Google Scholar
• Getsios D, Caro JJ, Ishak KJ et al. Oxybutynin extended release and tolterodine immediate release: a health economic comparison. Clin. Drug Investig. 24, 81–88 (2004).
   PubMedGoogle Scholar
• Getsios D, Caro JJ, Ishak KJ, El-Hadi W, Payne K. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder. Clin. Ther. 26(3), 431–438 (2004).
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jonsson L, Mattiasson A. Cost–effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol. Urodyn. 17(6), 599–611 (1998).
   PubMed Web of Science ®Google Scholar
• Arikian SR, Casciano J, Doyle JJ, Tarride JE, Casciano RN. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag. Care Interface 13(2), 88–94 (2000).
   PubMedGoogle Scholar
• Hall JA, Nelson MA, Meyer JW, Williamson T, Wagner S. Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data. Manag. Care Interface 14(8), 69–75 (2001).
   PubMedGoogle Scholar
• Yu YF, Yu AP, Ahn J et al. Comparison of direct healthcare cost hospital utilization and medication persistence between extended release forms (ER) of tolterodine and oxybutynin in overactive bladder/urinary incontinence patients. Value Health6,285 (2003).
   Google Scholar
• Becker RV, Noe LL, Trotter JP et al. A cost–effectiveness comparison of extended release tolterodine (Detrol® LA) versus controlled release oxybutynin (Ditropan® XL). Poster presented at: The 80th Annual Meeting of the South Central Section of the American Urological Association; September 12, TX, USA. (2001) Poster 236.
   Google Scholar
• McGhan WF. Cost–effectiveness and quality of life considerations in the treatment of patients with overactive bladder. Am. J. Manag. Care 7(S2), S62–S75 (2001).
   PubMedGoogle Scholar
• Zorn BH, Montgomery H, Pieper K et al. Urinary incontinence and depression. J. Urol.162,82–84 (1999).
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Kreder KJ, Pleil AM et al. Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am. J. Manag. Care8, S616–S630 (2002).
   Google Scholar
• Hunskaar S, Visnes A. The quality of life in women with urinary incontinence as measured by the Sickness Impact Profile. J. Am. Geriatr. Soc.39,378–382 (1991).
   PubMed Web of Science ®Google Scholar
• Grimby A, Milson I, Molander U et al. The influence of urinary incontinence on the QOL of elderly women. Age. Ageing 22, 82–89 (1993).
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. Br. J. Urol. 95(1), 81–85 (2005).
   Google Scholar
• Wiedemann A, Monser C, Braun W et al. Socio-economic aspects of urinary incontinence: savings potential through anticholinergics. Urologe B. 38, 154–159 (1998).
   Google Scholar
• Kim YH, Seo JT, Yoon H. The effect of overactive bladder syndrome on the sexual quality of life in Korean young and middle aged women. Int. J. Impot. Res. 17(2), 158–163 (2005).
   PubMed Web of Science ®Google Scholar
• Woodman PJ, Misko CA, Fischer JR. The use of short-form quality of life questionnaires to measure the impact of imipramine on women with urge incontinence. Int. Urogynecol. J. Pelvic Floor Dysfunct. 12(5), 312–315 (2001).
   PubMedGoogle Scholar
• Boccuzzi SJ, Le TK, Wogen J et al. Utilization patterns associated with tolterodine immediate release versus oxybutynin in the management of urinary incontinence (UI). Value Health 5, 274 (2002).
   Google Scholar
• Dmochowski RR, Sand PK, Zinner NR et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 62, 237–242 (2003).
   PubMed Web of Science ®Google Scholar
• Murray MD, Morrow DG, Weiner M et al. A conceptual framework to study medication adherence in older adults. Am J Geriatr Pharmacother.2(1), 36–43 (2004).
   PubMedGoogle Scholar
• Frank C. Urinary incontinence. Keeping family physicians involved in care. Can. Fam. Physician 48, 15–16 (2002).
   PubMedGoogle Scholar
• Seim A, Hunskaar S. Female urinary incontinence-the role of the general practitioner. Acta Obstet. Gynecol. Scand. 79(12), 1046–1051 (2000).
   PubMed Web of Science ®Google Scholar
• Stewart K, McGhan WF, Offerdahl T, Corey R. Overactive bladder patients and role of the pharmacist. J. Am. Pharm. Assoc. 42(3), 469–476 (2002).
   Google Scholar
• Aday LA, Begley CE, Lairson DR et al. In: Evaluating the Healthcare System: Effectiveness, Efficiency, and Equity. Health Administration Press, IL, USA (2004).
   Google Scholar